Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
Description
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that...
This week’s podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the...
Published 11/12/24
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,...
Published 11/06/24